ArticleInternational journal of clinical and experimental pathology2017
IGF-1R promotes the expression of cyclin D1 protein and accelerates the G1/S transition by activating Ras/Raf/MEK/ERK signaling pathway.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Antioxidant and Anti-Aging Effects of Porphyra-334 Produced fromMarine drugs · 2026Article
- Sustained-Release Sitagliptin Microneedles for Scar Prevention via Fibroblast-to-Adipocyte Conversion.Small science · 2025Article
- Dietary Restrictions and Cancer Prevention: State of the Art.Nutrients · 2025Review
- Insulin-like growth factor 1 (IGF-1)-induced changes in cardiac inducible nitric oxide synthase (iNOS) in obese rats.Frontiers in endocrinology · 2025Article
- Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.Archives of gynecology and obstetrics · 2022Article
- Decoding Insulin-Like Growth Factor Signaling Pathway From a Non-coding RNAs Perspective: A Step Towards Precision Oncology in Breast Cancer.Journal of mammary gland biology and neoplasia · 2022Review
- Involvement of IGF-1R-PI3K-AKT-mTOR pathway in increased number of GnRH3 neurons during androgen-induced sex reversal of the brain in female tilapia.Scientific reports · 2022Article
- Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer.Frontiers in pharmacology · 2021Review
- Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and InvasionFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of study was to detect the expression level of IGF-1R in breast cancer tissues and investigate the effect of IGF-1R expression on the proliferation and apoptosis of breast cancer cells.
methodsThe expression of IGF-1R protein in breast cancer tissues and the adjacent normal tissues was detected by immunohistochemistry. By IGF-1R inhibitor mediated repression of IGF-1R expression in MCF-7 cells, the cell proliferation rate, cell cycle and the expression of Ras/Raf/MEK/ERK signaling pathway proteins as well as cyclin D1 protein were examined in the IGF-1R-inhibited cells.
resultsThe proportion of IGF-1R, cyclin D1, Ras and p-ERK1/2 positive cells in breast cancer tissues were (69.8±12.7)%, (38.0±6.2)%, (71.6±10.3)% and (3.1±5.7)%, respectively, which were all significantly higher than those in the adjacent normal tissues [(16.2±6.7)%, (0.5±0.7)%, (7.1±0.9)% and (12.2±5.4)%] (P<0.05). Compared to normal MCF-7 cells, the MCF-7 cells treated with IGF-1R inhibitor showed no expression of IGF-1R protein, increased apoptosis rate (370.3%), increased proportion of cells in G1 phase (81.1%), decreased proportion of cells in S phase (66.8%), decreased proportion of cells in G2/M phase (52.9%), decreased Ras protein expression (70.9%), decreased p-ERK1/2 protein expression (53.3%), decreased cyclin D1 protein expression (59.5%), and substantially unchanged expression of ERK1/2 protein (P<0.05).
conclusionsIGF-1R is overexpressed in breast cancer tissues. The overexpressed IGF-1R promotes the expression of cyclin D1 protein and accelerates the G1/S transition by activating Ras/Raf/MEK/ERK signaling pathway, thus further promoting cell proliferation and the carcinogenesis of breast cancer.
Indexed as
Identifiers
31966523PMC6966087W3011030750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.